Compare Abbott India with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs TORRENT PHARMA - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA TORRENT PHARMA ABBOTT INDIA/
TORRENT PHARMA
 
P/E (TTM) x 54.2 54.4 99.5% View Chart
P/BV x 13.1 6.5 200.5% View Chart
Dividend Yield % 0.5 0.8 66.9%  

Financials

 ABBOTT INDIA   TORRENT PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-19
TORRENT PHARMA
Mar-18
ABBOTT INDIA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs8,8341,550 569.9%   
Low Rs5,4581,144 477.3%   
Sales per share (Unadj.) Rs1,731.1354.7 488.1%  
Earnings per share (Unadj.) Rs211.940.1 528.8%  
Cash flow per share (Unadj.) Rs219.964.2 342.4%  
Dividends per share (Unadj.) Rs65.0014.00 464.3%  
Dividend yield (eoy) %0.91.0 87.5%  
Book value per share (Unadj.) Rs945.2273.1 346.0%  
Shares outstanding (eoy) m21.25169.22 12.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.13.8 108.7%   
Avg P/E ratio x33.733.6 100.3%  
P/CF ratio (eoy) x32.521.0 155.0%  
Price / Book Value ratio x7.64.9 153.3%  
Dividend payout %30.734.9 87.8%   
Avg Mkt Cap Rs m151,848227,897 66.6%   
No. of employees `0003.514.7 23.7%   
Total wages/salary Rs m4,35611,353 38.4%   
Avg. sales/employee Rs Th10,555.54,083.0 258.5%   
Avg. wages/employee Rs Th1,249.9772.3 161.8%   
Avg. net profit/employee Rs Th1,292.2461.3 280.1%   
INCOME DATA
Net Sales Rs m36,78660,021 61.3%  
Other income Rs m1,1332,988 37.9%   
Total revenues Rs m37,91963,009 60.2%   
Gross profit Rs m6,04713,493 44.8%  
Depreciation Rs m1694,086 4.1%   
Interest Rs m233,085 0.7%   
Profit before tax Rs m6,9899,310 75.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,4852,529 98.3%   
Profit after tax Rs m4,5036,781 66.4%  
Gross profit margin %16.422.5 73.1%  
Effective tax rate %35.627.2 130.9%   
Net profit margin %12.211.3 108.4%  
BALANCE SHEET DATA
Current assets Rs m27,61052,623 52.5%   
Current liabilities Rs m8,56952,022 16.5%   
Net working cap to sales %51.81.0 5,165.0%  
Current ratio x3.21.0 318.5%  
Inventory Days Days60120 50.4%  
Debtors Days Days2776 35.9%  
Net fixed assets Rs m1,05785,016 1.2%   
Share capital Rs m213846 25.1%   
"Free" reserves Rs m19,87345,376 43.8%   
Net worth Rs m20,08646,222 43.5%   
Long term debt Rs m041,115 0.0%   
Total assets Rs m29,409142,432 20.6%  
Interest coverage x311.64.0 7,755.0%   
Debt to equity ratio x00.9 0.0%  
Sales to assets ratio x1.30.4 296.8%   
Return on assets %15.46.9 222.2%  
Return on equity %22.414.7 152.8%  
Return on capital %34.914.2 245.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36914,580 2.5%   
Fx outflow Rs m4,9183,600 136.6%   
Net fx Rs m-4,54910,980 -41.4%   
CASH FLOW
From Operations Rs m4,9918,942 55.8%  
From Investments Rs m-2,570-47,070 5.5%  
From Financial Activity Rs m-1,42834,174 -4.2%  
Net Cashflow Rs m993-3,655 -27.2%  

Share Holding

Indian Promoters % 0.0 71.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 7.0 112.5%  
FIIs % 0.1 12.6 0.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 8.8 194.3%  
Shareholders   18,270 26,511 68.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   PANACEA BIOTECH  BIOCON   FULFORD INDIA  ALKEM LABORATORIES  AJANTA PHARMA  

Compare ABBOTT INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 70 Points Higher; Telecom and Banking Stocks Advance(Closing)

Indian share markets traded on a positive note throughout the day and ended marginally higher. The BSE Sensex rose over 350 points intraday.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Nov 15, 2019 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS